BC |
Breast Cancer |
miRNA |
MicroRNA |
Bak1 |
Pro-apoptotic Bcl2 antagonist killer 1 |
DAPK2 |
Death-Associated kinase 2 |
TSP-1 |
Thrombospondin-1 |
MCL-1 |
Myeloid cell leukemia |
EIF4E |
Eukaryotic translation initiation factor 4E |
CP110 |
Centriolar coiled-coil protein 110 |
APC4 |
Anaphase promoting complex subunit 4 |
HSPG2 |
Heparin sulfate proteoglycan 2 |
CCND1 |
Cyclin D1 |
PTEN |
Phosphatase and tensin homolog |
ERα |
Estrogen receptor α |
SERDs |
Selective estrogen receptor downregulators |
SERMs |
Selective ER modulators |
TCGA |
The cancer genome atlas |
ASCO |
American society of clinical oncology |
GEMIN4 |
Gem nuclear organelle associated protein 4 |
BMP7 |
Bone morphogenetic protein 7 |
UCP2 |
Uncoupling protein 2 |
HDAC4 |
Histone deacetylase |
SOC6 |
Suppressor of cytokine signaling 6 |
HER2 |
Human epidermal growth factor receptor-2 |
EMT |
Epithelial to mesenchymal transition |
IGF1R |
Insulin-like growth factor-1 receptor |
TKI |
Tyrosine kinase inhibitor |
FDA |
Food and drug administration |
CCNJ |
Cyclin J |
FUBP1 |
Far upstream element binding protein 1 |
TNBC |
Triple negative breast cancer |
IL-6 |
Interleukine-6 |